Cargando…
Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820607/ https://www.ncbi.nlm.nih.gov/pubmed/31587095 http://dx.doi.org/10.1007/s00280-019-03964-6 |
| _version_ | 1783463985366958080 |
|---|---|
| author | Rivera, Fernando Romero, C. Jimenez-Fonseca, P. Izquierdo-Manuel, M. Salud, A. Martínez, E. Jorge, M. Arrazubi, V. Méndez, J. C. García-Alfonso, P. Reboredo, M. Barriuso, J. Muñoz-Unceta, N. Jimeno, R. López, C. |
| author_facet | Rivera, Fernando Romero, C. Jimenez-Fonseca, P. Izquierdo-Manuel, M. Salud, A. Martínez, E. Jorge, M. Arrazubi, V. Méndez, J. C. García-Alfonso, P. Reboredo, M. Barriuso, J. Muñoz-Unceta, N. Jimeno, R. López, C. |
| author_sort | Rivera, Fernando |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6820607 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68206072019-11-06 Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial Rivera, Fernando Romero, C. Jimenez-Fonseca, P. Izquierdo-Manuel, M. Salud, A. Martínez, E. Jorge, M. Arrazubi, V. Méndez, J. C. García-Alfonso, P. Reboredo, M. Barriuso, J. Muñoz-Unceta, N. Jimeno, R. López, C. Cancer Chemother Pharmacol Correction Springer Berlin Heidelberg 2019-10-05 2019 /pmc/articles/PMC6820607/ /pubmed/31587095 http://dx.doi.org/10.1007/s00280-019-03964-6 Text en © The Author(s) 2019, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
| spellingShingle | Correction Rivera, Fernando Romero, C. Jimenez-Fonseca, P. Izquierdo-Manuel, M. Salud, A. Martínez, E. Jorge, M. Arrazubi, V. Méndez, J. C. García-Alfonso, P. Reboredo, M. Barriuso, J. Muñoz-Unceta, N. Jimeno, R. López, C. Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title | Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title_full | Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title_fullStr | Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title_full_unstemmed | Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title_short | Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial |
| title_sort | correction to: phase ii study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of her2-positive advanced gastric cancer: herxo trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820607/ https://www.ncbi.nlm.nih.gov/pubmed/31587095 http://dx.doi.org/10.1007/s00280-019-03964-6 |
| work_keys_str_mv | AT riverafernando correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT romeroc correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT jimenezfonsecap correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT izquierdomanuelm correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT saluda correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT martineze correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT jorgem correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT arrazubiv correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT mendezjc correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT garciaalfonsop correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT reboredom correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT barriusoj correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT munozuncetan correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT jimenor correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial AT lopezc correctiontophaseiistudytoevaluatetheefficacyoftrastuzumabincombinationwithcapecitabineandoxaliplatininfirstlinetreatmentofher2positiveadvancedgastriccancerherxotrial |